Literature DB >> 14576099

Synthesis, degradation, and antimicrobial properties of targeted macromolecular prodrugs of norfloxacin.

Eveline Roseeuw1, Veerle Coessens, Anne-Marie Balazuc, Micheline Lagranderie, Pierre Chavarot, Augusto Pessina, Maria Grazia Neri, Etienne Schacht, Gilles Marchal, Dominique Domurado.   

Abstract

Long-term antibiotic treatment is required to cure tuberculosis. Targeted antibiotics should improve the efficacy of treatment by concentrating the drugs close to the bacteria. The aim of the present study was to synthesize targeted conjugates. For this purpose, we used mannose as a homing device to direct norfloxacin into macrophages. Dextran was used as the polymer bearing both mannose and norfloxacin. Using different peptide spacer arms to link norfloxacin to dextran, we demonstrated that norfloxacin acts as an antibiotic only when it is released in its native form. Also, targeting by using mannose as a homing device is required to achieve antimycobacterial activity in vivo. Thus, norfloxacin, which is inactive against mycobacteria in its native form in vivo, can be transformed into an active drug by targeting.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14576099      PMCID: PMC253810          DOI: 10.1128/AAC.47.11.3435-3441.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  5 in total

Review 1.  Commentary. Lysosomotropic agents.

Authors:  C de Duve; T de Barsy; B Poole; A Trouet; P Tulkens; F Van Hoof
Journal:  Biochem Pharmacol       Date:  1974-09-15       Impact factor: 5.858

2.  Influence of barrier-crossing limitations on the amount of macromolecular drug taken up by its target.

Authors:  A Aubrée-Lecat; M C Duban; S Demignot; M Domurado; P Fournié; D Domurado
Journal:  J Pharmacokinet Biopharm       Date:  1993-02

3.  Viability, heat stability and immunogenicity of four BCG vaccines prepared from four different BCG strains.

Authors:  M Gheorghiu; P H Lagrange
Journal:  Ann Immunol (Paris)       Date:  1983 Jan-Feb

4.  Ligand recognition by purified human mannose receptor.

Authors:  V Kéry; J J Krepinský; C D Warren; P Capek; P D Stahl
Journal:  Arch Biochem Biophys       Date:  1992-10       Impact factor: 4.013

5.  The Mycobacterium tuberculosis phagosome interacts with early endosomes and is accessible to exogenously administered transferrin.

Authors:  D L Clemens; M A Horwitz
Journal:  J Exp Med       Date:  1996-10-01       Impact factor: 14.307

  5 in total
  5 in total

1.  Novel conjugate of moxifloxacin and carboxymethylated glucan with enhanced activity against Mycobacterium tuberculosis.

Authors:  Y S Schwartz; M I Dushkin; V A Vavilin; E V Melnikova; O M Khoschenko; V A Kozlov; A P Agafonov; A Y Alekseev; Y Rassadkin; A M Shestapalov; M S Azaev; D V Saraev; P N Filimonov; Y Kurunov; A V Svistelnik; V A Krasnov; A Pathak; S C Derrick; R C Reynolds; S Morris; V M Blinov
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

2.  Macrophage-specific targeting of isoniazid through mannosylated gelatin microspheres.

Authors:  Sanjay Tiwari; Adya P Chaturvedi; Yamini B Tripathi; Brahmeshwar Mishra
Journal:  AAPS PharmSciTech       Date:  2011-07-06       Impact factor: 3.246

Review 3.  Prodrugs for the treatment of neglected diseases.

Authors:  Man Chin Chung; Elizabeth Igne Ferreira; Jean Leandro Santos; Jeanine Giarolla; Daniela Gonçales Rando; Adélia Emília Almeida; Priscila Longhin Bosquesi; Renato Farina Menegon; Lorena Blau
Journal:  Molecules       Date:  2007-03-19       Impact factor: 4.411

Review 4.  Can formulation and drug delivery reduce attrition during drug discovery and development-review of feasibility, benefits and challenges.

Authors:  S Basavaraj; Guru V Betageri
Journal:  Acta Pharm Sin B       Date:  2014-01-24       Impact factor: 11.413

Review 5.  Macromolecular Conjugate and Biological Carrier Approaches for the Targeted Delivery of Antibiotics.

Authors:  Nhan Dai Thien Tram; Pui Lai Rachel Ee
Journal:  Antibiotics (Basel)       Date:  2017-07-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.